title: The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats.
abstract: Adriamycin (ADR) is a potent antitumor antibiotic drug known to cause severe cardiac toxicity. Although ADR generates free radicals, the role of these radicals in the development of cardiac toxicity is still not well understood. In the present study, we evaluated the effect of glutathione (GSH) supplementation or depletion on ADR-induced cardiotoxicity in male Wistar rats. Cardiac toxicity was induced by a single intraperitoneal injection of ADR (20 mg kg(-1)) and manifested by an increase in heart rate, blood pressure elevation, and increased serum creatine kinase (CK) and lactate dehydrogenase (LDH). The extent of lipoprotein oxidation, lipid peroxide measured as malondialdhye (MDA), total homocysteine (tHcy), lipid profile, and atherogenic index were markedly elevated, whereas cardiac GSH content was dramatically decreased in ADR rats. Pre- and co-treatment of ADR rats with GSH (5 mm kg(-1)) (ADR +GSH) markedly reduced the levels of CK, LDH, lipoprotein oxidation susceptibility, cardiac MDA, tHcy and atherogenic index, and elevated GSH levels in cardiac tissues. In contrast, GSH depletion through administration of l-buthionine-(S,R)-sulfoximine (BSO) (15 mm kg(-1)) before and after ADR injection (ADR +BSO) greatly exacerbated ADR cardiotoxicity compared to the control and ADR groups. Finally, there were also severe cardiac histopathological changes in ADR and ADR +BSO groups, which were nearly restored by GSH treatment. These results suggest that GSH inhibits ADR cardiotoxicity and might serve as a novel combination with ADR to limit free radical-mediated organ injury.
authors.affiliation: Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
authors.forename: H E
authors.initials: HE
authors.lastname: Mohamed
authors.forename: S E
authors.initials: SE
authors.lastname: El-Swefy
authors.forename: H H
authors.initials: HH
authors.lastname: Hagar
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D000963:Antimetabolites / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D019328:Buthionine Sulfoximine / Q000494:pharmacology; D003402:Creatine Kinase / Q000097:blood; D004317:Doxorubicin / Q000633:toxicity*; D005978:Glutathione / Q000172:deficiency / Q000494:pharmacology* / Q000502:physiology; D006331:Heart Diseases / Q000139:chemically induced* / Q000378:metabolism / Q000517:prevention & control*; D006339:Heart Rate / Q000187:drug effects; D006710:Homocysteine / Q000378:metabolism; D007770:L-Lactate Dehydrogenase / Q000097:blood; D015227:Lipid Peroxidation / Q000187:drug effects; D008074:Lipoproteins / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D008074:Lipoproteins; D006710:Homocysteine; D008315:Malondialdehyde; D019328:Buthionine Sulfoximine; D004317:Doxorubicin; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase; D005978:Glutathione